Key result
68Ga-linagliptin PET/CT increased tracer uptake in inflamed myocardium of viral myocarditis mice at 7 days, correlating with histological inflammation.
Why the study?
Myocarditis, which is primarily induced by viral infection, lacks reliable non-invasive imaging for early diagnosis. This study developed a novel DPP4-targeted PET probe, 68Ga-DOTA-linagliptin, to assess its potential in detecting cardiac inflammation in viral myocarditis.
Does the DPP4-targeted PET probe 68Ga-DOTA-linagliptin enable non-invasive visualization of cardiac inflammation and does linagliptin attenuate myocardial inflammation in mice with Coxsackievirus B3-induced viral myocarditis?
Does the DPP4-targeted PET probe 68Ga-DOTA-linagliptin enable non-invasive visualization of cardiac inflammation and does linagliptin attenuate myocardial inflammation in mice with Coxsackievirus B3-induced viral myocarditis?
The novel DPP4-targeted PET probe 68Ga-DOTA-linagliptin enables sensitive, non-invasive visualization of infiltrating immune cell-driven cardiac inflammation in experimental viral myocarditis, while unlabeled linagliptin pretreatment attenuates myocardial inflammation and improves cardiac function.
Answers are grounded in this paper and cite their sources.
May advance DPP4-targeted PET for preclinical myocarditis imaging; leaves open human translation pending trials.
Myocarditis, primarily induced by viral infection, lacks reliable non-invasive imaging for early diagnosis. We developed a novel PET probe, ⁶⁸Ga-DOTA-linagliptin (abbreviated as ⁶⁸Ga-linagliptin), which targets dipeptidyl peptidase-4 (DPP4), to assess its potential in detecting myocarditis. Western blotting and immunostaining showed an elevated cardiac DPP4 expression in mice with Coxsackievirus B3 (CVB3) myocarditis. Single-cell sequencing analysis and cardiac flow cytometry further revealed that the elevated DPP4 expression predominantly originated from infiltrating immune cells, including T cells, dendritic cells, and B cells. Molecular docking and dynamics simulations, together with a DPP4 enzyme inhibition assay, demonstrated high-affinity and direct binding between ⁶⁸Ga-linagliptin and DPP4. ⁶⁸Ga-linagliptin showed favorable pharmacokinetics in vivo and shows significantly higher probe uptake in DPP4-overexpressing cells in vitro and in vivo. PET/CT imaging revealed pronounced ⁶⁸Ga-linagliptin accumulation within the inflamed myocardium of mice with myocarditis, with minimal uptake in control animals. The PET/CT signal distribution closely matched histologically identified inflammatory regions. Moreover, pretreatment with the unlabeled precursor drug linagliptin effectively attenuated inflammation and improved cardiac function in CVB3-infected mice. These findings indicate that ⁶⁸Ga-linagliptin enables sensitive and non-invasive visualization of cardiac inflammation and may offer combined diagnostic and therapeutic benefits for viral myocarditis.
No takes yet. Share an insight, caveat, or question.
Gao et al. (2026) studied Coxsackievirus B3 (CVB3)-induced viral myocarditis. 68Ga-DOTA-linagliptin (68Ga-linagliptin) PET/CT imaging and oral linagliptin treatment vs. Uninfected sham controls (PBS), competitive blocking with unlabeled linagliptin, and 68Ga-PSMA control tracer was evaluated on Myocardial accumulation of 68Ga-linagliptin and its correlation with histological inflammatory infiltration area at 7 days post-infection (r = 0.7491, p=0.005). 68Ga-linagliptin PET/CT increased tracer uptake in inflamed myocardium of viral myocarditis mice at 7 days, correlating with histological inflammation.
Synapse has enriched 10 related papers. Consider them for comparative context: